Wacker will soon open a competence center for active ingredients based on messenger ribonucleic acid (mRNA) at its location in Halle, Germany supported by its partner, Pantherna.
Wacker Biotech GmbH, a wholly owned subsidiary of Wacker Chemie AG, will use four new production lines at the site to produce mRNA vaccines.
Related: PCHi Illuminates 17 Fountain Award Winners, 800+ Exhibitors and 30K Attendees
Guido Seidel, Ph.D., managing director of Wacker Biotech GmbH, commented: “The early collaboration with Pantherna made it possible to develop a cost-efficient and scalable process. In preclinical phases, this is rare in the CDMO environment. The close cooperation with our experts in central research was the key to success here. The technology transfer to our new production facility is now in full swing and we are sure that Pantherna will benefit from our manufacturing expertise.”
